Total (N = 42) | Anal swab test positive (n = 6) | Anal swab test negative (n = 36) | P Valuea | |
---|---|---|---|---|
Sex | ||||
Female | 25(59.5%) | 6(100.0%) | 19(52.8%) | 0.031 |
Male | 17(40.5%) | 0(0.0%) | 17(47.2%) | |
Age, median (IQR), y | 40(30.8 ~ 46.0) | 28.5(13.3 ~ 50.5) | 42(32 ~ 46) | 0.250 |
>50 | 9(21.4%) | 1(16.7%) | 8(22.2%) | 0.762 |
≤ 50 | 33(78.6%) | 5(83.3%) | 28(77.8%) | |
BMI, median (IQR) | 24.4(22.2 ~ 25.7) | 24.6(16.0 ~ 27.9) | 24.1(22.2 ~ 25.6) | 1.000 |
Epidemiology | ||||
Direct exposure history | 22(52.4%) | 2(33.3%) | 20(55.6%) | 0.148 |
Indirect exposure history | 6(14.3%) | 0(0.0%) | 6(16.7%) | |
Family outbreak | 14(33.3%) | 4(66.7%) | 10(27.8%) | |
Incubation period, median (IQR), d | 7(3 ~ 10) | 9(4.5 ~ 11.3) | 6.5(3 ~ 10) | 0.320 |
Onset of symptom to, median (IQR), d | ||||
Hospital admission | 3.5(2 ~ 6) | 3.0(2 ~ 5.5) | 3.5(2 ~ 6) | 0.697 |
Anal swab test | 27(25 ~ 32.3) | 26.5(21.5 ~ 35.3) | 27(25 ~ 32.3) | 0.836 |
Signs and symptoms | ||||
Fever | 29(69.0%) | 3(50.0%) | 26(72.2%) | 0.281 |
Maximum temperature, median (IQR), °C | 37.7(36.8 ~ 38.5) | 37.2(36.1 ~ 38.2) | 37.9(37.0 ~ 38.7) | 0.235 |
<37·3 | 13(31.0%) | 3(50.0%) | 10(27.8%) | 0.541 |
37·3–38 | 14(33.3%) | 2(33.3%) | 12(33.3%) | |
38·1–39 | 8(19.0%)) | 0(0.0%) | 8(22.2%) | |
>39 | 7(16.7%) | 1(16.7%) | 6(16.7%) | |
Cough | 35(83.3%) | 4(66.7%) | 31(86.1%) | 0.242 |
Dyspnea | 3(7.1%) | 1(16.7%) | 2(5.6%) | 0.333 |
Fatigue | 3(7.1%) | 1(16.7%) | 2(5.6%) | 0.333 |
Myalgia | 5(11.9%) | 0(0.0%) | 5(13.9%) | 0.336 |
Headache | 4(9.5%) | 0(0.0%) | 4(11.1%) | 0.396 |
Nausea and vomiting | 1(2.4%) | 0(0.0%) | 1(2.8%) | 0.683 |
Diarrhea | 6(14.3%) | 0(0.0%) | 6(16.7%) | 0.285 |
No symptoms | 4(9.5%) | 2(33.3%) | 2(5.6%) | 0.034 |
Comorbidities | ||||
Diabetes | 2(4.8%) | 0(0.0%) | 2(5.6%) | 0.558 |
Hypertension | 2(4.8%) | 0(0.0%) | 2(5.6%) | 0.558 |
Hepatitis or liver cirrhosis | 2(4.8%) | 0(0.0%) | 2(5.6%) | 0.558 |
Chronic renal failure | 1(2.4%) | 0(0.0%) | 1(2.8%) | 0.683 |
Malignancy | 1(2.4%) | 0(0.0%) | 1(2.8%) | 0.683 |
Digestive diseases | 3(7.1%) | 1(16.7%) | 2(5.6%) | 0.333 |
Clinical type | ||||
Mild type | 2(4.8%) | 1(16.7%) | 1(2.8%) | 0.701 |
Common type | 30(71.4%) | 3(50.0%) | 27(75.0%) | |
Severe type | 7(16.7%) | 2(33.3%) | 5(13.9%) | |
Critical type | 3(7.1%) | 0(0.0%) | 3(8.3%) | |
Mild + Common type | 32(76.2%) | 4(66.7%) | 28(77.8%) | 0.558 |
Severe + Critical type | 10(23.8) | 2(33.3%) | 8(22.2%) | |
Treatment | ||||
Antibiotic | 29(69.0%) | 3(50.0%) | 26 (72.2%) | 0.281 |
Duration of antibiotic | 6.5(0 ~ 8.3) | 2.5(0 ~ 10.5) | 7.0(0 ~ 8) | 0.562 |
Glucocorticoid | 29(69.0%) | 4(66.7%) | 25(69.4%) | 0.892 |
Duration of glucocorticoid | 4(0 ~ 5) | 4.5(0 ~ 6.5) | 4(0 ~ 5) | 0.739 |
Non-Invasive Ventilation | 3(7.1%) | 1(16.7%) | 2(5.6%) | 0.333 |
Duration of throat swab positive, median (IQR), d | 7.5(5 ~ 10.3) | 10.0(7.3 ~ 12.3) | 7.0(3 ~ 10) | 0.208 |
Duration of fever, median (IQR), d | 5(0.8 ~ 9.3) | 1(0 ~ 6.3) | 6(2 ~ 9.8) | 0.120 |
Duration of major symptoms (except fever), median (IQR), d | 8.5(3.8 ~ 13.3) | 4.5(0 ~ 5.5) | 10.5(4.3 ~ 14) | 0.022 |
Hospital stays, median (IQR), d | 12.5(9 ~ 18) | 14.5(11 ~ 20.3) | 11.5(9 ~ 17.5) | 0.471 |